These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17689883)

  • 1. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
    Che M; DeSilvio M; Pollack A; Grignon DJ; Venkatesan VM; Hanks GE; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1117-23. PubMed ID: 17689883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
    Chakravarti A; DeSilvio M; Zhang M; Grignon D; Rosenthal S; Asbell SO; Hanks G; Sandler HM; Khor LY; Pollack A; Shipley W;
    J Clin Oncol; 2007 Jul; 25(21):3082-9. PubMed ID: 17634487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
    Khor LY; Bae K; Pollack A; Hammond ME; Grignon DJ; Venkatesan VM; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Dicker AP
    Lancet Oncol; 2007 Oct; 8(10):912-20. PubMed ID: 17881290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
    J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
    Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
    J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
    Khor LY; Bae K; Paulus R; Al-Saleem T; Hammond ME; Grignon DJ; Che M; Venkatesan V; Byhardt RW; Rotman M; Hanks GE; Sandler HM; Pollack A
    J Clin Oncol; 2009 Jul; 27(19):3177-84. PubMed ID: 19470936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
    Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610.
    Zhang M; Ho A; Hammond EH; Suzuki Y; Bermudez RS; Lee RJ; Pilepich M; Shipley WU; Sandler H; Khor LY; Pollack A; Chakravarti A
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1033-42. PubMed ID: 18977097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
    Khor LY; Moughan J; Al-Saleem T; Hammond EH; Venkatesan V; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Pollack A
    Clin Cancer Res; 2007 Jun; 13(12):3585-90. PubMed ID: 17575222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
    Pollack A; Grignon DJ; Heydon KH; Hammond EH; Lawton CA; Mesic JB; Fu KK; Porter AT; Abrams RA; Shipley WU
    J Clin Oncol; 2003 Apr; 21(7):1238-48. PubMed ID: 12663710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
    Johnson S; Jackson W; Li D; Song Y; Foster C; Foster B; Zhou J; Vainshtein J; Feng F; Hamstra D
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):554-61. PubMed ID: 23561650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.
    Bekelman JE; Mitra N; Handorf EA; Uzzo RG; Hahn SA; Polsky D; Armstrong K
    J Clin Oncol; 2015 Mar; 33(7):716-22. PubMed ID: 25559808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.